PR Newswire
LEWES, Del., April 15, 2026
The Downstream Processing Market is entering a high-stakes expansion phase driven by surging biopharmaceutical production, intensified demand for monoclonal antibodies, and rapid scale-up of cell and gene therapies. Market dynamics reveal strong momentum across purification technologies, chromatography resins, and filtration systems as manufacturers pursue higher yield, purity, and process efficiency. Innovation in single-use systems, continuous bioprocessing, and membrane-based separation is redefining cost structures and operational scalability. Emerging applications across personalized medicine and biosimilars are unlocking new revenue pockets, strengthening pipeline intensity, and accelerating commercialization timelines across global biomanufacturing ecosystems.
LEWES, Del., April 15, 2026 /PRNewswire/ — The Global Downstream Processing Market is projected to grow at a CAGR of 6.8% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals that the market was valued at USD 12.5 Billion in 2024 and is expected to reach USD 20.3 Billion by the end of the forecast period.
https://mma.prnewswire.com/media/2486715/5468917/VM_Reports.jpg
Download PDF Brochure:
https://www.verifiedmarketreports.com/download-sample/?rid=32884&utm_source=PRNewswire&utm_medium=360
Browse in-depth TOC on Downstream Processing Market
150 – Pages
126 – Tables
37 – Figures
Scope of The
Downstream Processing Market
Report
REPORT ATTRIBUTES
DETAILS
STUDY PERIOD
2023-2033
BASE YEAR 2024
FORECAST PERIOD
2026-2033
HISTORICAL PERIOD 2023
ESTIMATED PERIOD 2025
UNIT
Value (USD Billion)
KEY COMPANIES PROFILED Thermo Fisher Scientific Inc., GE Healthcare, Sartorius Stedim Biotech S.A., Merck Millipore, Danaher
Corporation, 3M Company, Boehringer Ingelheim, Lonza Group AG, Eppendorf AG, Finesse SolutionsInc
SEGMENTS COVERED
By Type, By End-Use, By Scale, By Product Type, By Technology, By Geography
CUSTOMIZATION SCOPE Free report customization (equivalent to up to 4 analyst working days) with purchase. Addition or alteration
to country, regional & segment scope
Executive Summary of Downstream Processing Market
The Downstream Processing Market represents a critical value-capture layer within the biopharmaceutical and biotechnology production ecosystem, directly influencing yield efficiency, product purity, and regulatory compliance. This report delivers institutional-grade intelligence by synthesizing multi-source datasets, including financial disclosures, patent landscapes, clinical pipeline evolution, and capital deployment trends. It provides investors, private equity firms, and strategic acquirers with actionable insights into revenue expansion pathways, margin optimization levers, and competitive positioning across chromatography, filtration, and purification technologies. The analysis is structured to support capital allocation decisions, identify white-space innovation opportunities, and benchmark operational efficiency across leading bioprocessing firms.
Delivered through a combination of quantitative modeling, scenario-based forecasting, and qualitative industry validation, the report equips stakeholders with decision-ready intelligence. It highlights high-growth subsegments, emerging regional demand clusters, and evolving regulatory frameworks shaping investment risk-return profiles. By integrating AI-driven analytics, supply chain intelligence, and technology adoption curves, the report enables stakeholders to anticipate market inflection points, optimize portfolio exposure, and align with long-term biomanufacturing trends. The focus remains on translating complex technical developments into simplified, high-impact insights tailored for boardroom discussions and investment committees.
Downstream Processing Market Size & Forecast 2026-2033 | Leading Segments | Application
- Market size (2024): 12.5 Billion
- Forecast (2033): 20.3 Billion
- CAGR 2026-2033: 6.8%
- Leading Segments: Chromatography systems dominate revenue share exceeding 45%, followed by membrane filtration driven by monoclonal antibody production scalability.
- Key Application: Biopharmaceutical manufacturing contributes over 60% of demand, with vaccines and cell & gene therapy expanding rapidly.
- Key Regions/Countries with market share: North America leads with ~38% share, Europe holds ~27%, while China and India collectively exceed 18% with accelerating growth rates.
Downstream Processing Market Transformational Trends
Continuous bioprocessing is emerging as a dominant paradigm shift, replacing batch-based purification systems with integrated, real-time production workflows. This transition is projected to contribute nearly 30% incremental efficiency gains and reduce operational costs by up to 20%. Adoption remains in early-to-mid diffusion stages but is accelerating in North America and Western Europe due to regulatory encouragement and capital investments exceeding USD 5 billion annually. Enabling technologies include single-use systems, advanced sensors, and AI-driven process optimization. Regulatory bodies are increasingly supporting continuous manufacturing frameworks, reducing approval timelines. Competitive positioning is shifting toward firms offering integrated end-to-end solutions, while risks include high upfront capital expenditure and technical complexity in scaling.
Single-use technologies are redefining cost structures and operational flexibility within the Downstream Processing Market. These systems eliminate cleaning validation requirements and reduce contamination risks, contributing to approximately 25% faster turnaround times. Adoption is in the early majority phase, with strong uptake in Asia-Pacific due to greenfield facility expansion. The trend is supported by ESG considerations, as reduced water and energy consumption aligns with sustainability mandates. However, supply chain constraints for disposable components and waste management concerns present emerging risks. Companies investing in vertically integrated supply chains and recycling innovations are expected to capture higher margins and long-term competitive advantage.
Advanced chromatography innovations, including multi-column systems and continuous chromatography, are significantly enhancing purification efficiency and throughput. These technologies are projected to contribute over 40% of incremental revenue growth in high-value biologics manufacturing. Adoption is accelerating due to increasing demand for monoclonal antibodies and biosimilars. Investment inflows into chromatography innovation exceed USD 3 billion annually, driven by strategic partnerships and acquisitions. The competitive landscape is shifting toward technology leaders with strong intellectual property portfolios. Risks include high equipment costs and the need for specialized workforce training, which may limit adoption in emerging markets.
Digitalization and AI integration are transforming process optimization, predictive maintenance, and quality assurance within downstream operations. AI-driven analytics are enabling real-time monitoring and adaptive control systems, reducing batch failures by up to 35%. Adoption is in the early growth stage but is expected to scale rapidly with increasing digital maturity across biopharma firms. Regulatory frameworks are gradually incorporating digital validation standards, facilitating broader adoption. Key risks include cybersecurity vulnerabilities and integration challenges with legacy systems. Companies leveraging AI-enabled platforms are achieving superior operational efficiency and faster time-to-market.
Expansion of cell and gene therapy pipelines is driving demand for highly specialized downstream processing solutions. These therapies require precision purification techniques, creating high-margin opportunities for technology providers. The segment is expected to grow at a CAGR exceeding 18%, significantly outpacing the overall market. Investment inflows from venture capital and strategic partnerships are accelerating innovation. However, scalability challenges and regulatory complexities remain critical risks. Firms that can deliver scalable, compliant solutions are positioned to capture significant market share in this rapidly evolving segment.
To Purchase a Comprehensive Report Analysis:
https://www.verifiedmarketreports.com/ask-for-discount/?rid=32884&utm_source=PRNewswire&utm_medium=360
Downstream Processing Market Drivers and Restraints
Key Demand Drivers
- Rising biologics demand contributes over 50% of total revenue growth, driven by chronic disease prevalence.
- Expansion of biosimilars market reduces treatment costs, increasing adoption across emerging economies.
- Technological advancements in purification systems enhance yield efficiency by up to 30%.
- Increased R&D investments by pharmaceutical companies exceeding USD 200 billion annually.
- Regulatory support for advanced manufacturing accelerates commercialization timelines.
These drivers collectively create a strong positive regression impact on revenue growth, with biologics demand and R&D investment acting as primary accelerators. The correlation between technological innovation and revenue expansion remains high, with advanced systems directly improving production efficiency and profitability. Demographic shifts, including aging populations, further amplify demand. However, the effectiveness of these drivers depends on capital availability and regulatory alignment. Firms that align investment strategies with these drivers are expected to achieve above-average growth and market share expansion.
Key Market Restraints
- High capital expenditure requirements limit entry for small and mid-sized players.
- Complex regulatory compliance increases operational costs and delays approvals.
- Supply chain disruptions impact availability of critical components.
- Pricing pressure from biosimilars reduces profit margins.
- Skilled workforce shortage constrains technology adoption.
These restraints exhibit high likelihood and moderate-to-high impact within the risk matrix. Capital intensity and regulatory complexity are the most significant barriers, directly affecting market entry and scalability. Supply chain vulnerabilities have increased post-pandemic, highlighting the need for localized manufacturing. Pricing pressures are intensifying competition, forcing companies to optimize cost structures. Addressing these constraints requires strategic investments in automation, workforce development, and supply chain resilience to sustain long-term growth.
Downstream Processing Market Regional Analysis
North America remains the dominant region, driven by advanced biopharmaceutical infrastructure, high R&D expenditure, and strong regulatory frameworks. The United States accounts for the majority share, supported by leading biotechnology firms and continuous innovation in purification technologies. Investment inflows remain robust, with significant funding directed toward biologics and gene therapy manufacturing.
Europe holds a substantial share, with Germany, the UK, and Switzerland leading in bioprocessing innovation. Strong regulatory support and established pharmaceutical companies drive market growth. Sustainability initiatives and green manufacturing practices are gaining traction, influencing technology adoption.
Asia-Pacific is the fastest-growing region, led by China, India, and South Korea. Rapid expansion of biopharmaceutical manufacturing and favorable government policies are key growth drivers. Cost advantages and increasing domestic demand are attracting global investments.
The United States Downstream Processing Market benefits from a highly developed healthcare ecosystem and strong venture capital presence. Continuous innovation and early adoption of advanced technologies position the country as a global leader. Regulatory frameworks support rapid commercialization, enhancing market competitiveness.
Japan Downstream Processing Market is characterized by strong government support and advanced research capabilities. The country focuses on high-quality manufacturing and precision technologies. Aging population demographics drive demand for biologics, supporting market expansion.
South Korea Downstream Processing Market is emerging as a key player due to aggressive investments in biotechnology infrastructure. Government initiatives and partnerships with global firms are accelerating growth. The country is positioning itself as a regional hub for biomanufacturing.
Germany Downstream Processing Market leads in Europe with strong industrial capabilities and innovation in bioprocessing technologies. The country’s focus on sustainability and efficiency drives adoption of advanced systems. Strategic collaborations enhance global competitiveness.
Downstream Processing Market Competitive Landscape
The competitive landscape is dominated by established global players with strong portfolios in chromatography, filtration, and single-use technologies. These companies maintain high R&D intensity, often exceeding 10% of revenue, enabling continuous innovation and product differentiation.
Revenue benchmarking indicates consistent growth among leading firms, with annual revenues ranging between USD 5 billion and USD 30 billion. Geographic revenue distribution shows strong presence in North America and Europe, with increasing penetration in Asia-Pacific. Emerging challengers are focusing on niche technologies and cost-effective solutions, targeting mid-sized biopharmaceutical companies. These players are gaining traction through strategic partnerships and localized manufacturing capabilities.
Disruptive startups are leveraging AI and digital platforms to optimize downstream processes. Their innovation intensity is high, with significant venture capital funding supporting rapid development and commercialization. M&A activity remains strong, with large players acquiring innovative startups to expand technology portfolios and market reach. Vertical integration strategies are enhancing supply chain control and improving profit margins.
Downstream Processing Market Outlook 2026-2033
The market is expected to witness sustained growth driven by increasing demand for biologics and advanced therapies. Scenario-based forecasts indicate strong upside potential under favorable regulatory and economic conditions. Capital deployment is shifting toward high-growth segments such as cell and gene therapy, with significant investment opportunities for institutional investors. Strategic acquisitions are expected to accelerate market consolidation.
Risk-adjusted returns remain attractive, with technology-driven efficiency gains offsetting pricing pressures. Companies focusing on innovation and scalability are likely to outperform. Investors and C-suite executives should prioritize strategic partnerships, digital transformation, and regional expansion to capture long-term growth opportunities in the Downstream Processing Market.
Downstream Processing Market Recent Developments
- In March 2025, Thermo Fisher Scientific expanded its single-use bioprocessing facility in the United States to increase production capacity and meet rising biologics demand, strengthening supply chain resilience.
- In January 2025, Sartorius AG acquired a chromatography technology startup to enhance its purification portfolio and accelerate innovation in continuous processing.
- In 2024, Merck KGaA launched an advanced filtration system designed for high-efficiency biologics purification, improving yield and reducing processing time.
- In February 2025, Danaher Corporation announced a strategic partnership with a biotech firm to develop AI-driven downstream processing solutions, enhancing process optimization capabilities.
- In 2024, Cytiva invested in expanding its manufacturing footprint in Asia-Pacific, targeting increased demand from emerging biopharmaceutical markets.
Downstream Processing Market Methodology Appendix
The research methodology integrates multiple data sources, including consumer panels, proprietary telemetry, syndicated databases, financial reports, patent filings, and web scraping. Sampling quotas are designed to ensure representation across regions, company sizes, and technology segments. Raking adjustments and non-response bias correction techniques are applied to enhance data accuracy.
The analytics stack includes advanced NLP pipelines, sentiment analysis models, and topic clustering using LDA and BERTopic algorithms. Causal inference models and forecasting algorithms are employed to generate predictive insights. Validation protocols include holdout testing, back-testing, and sensitivity analysis to ensure robustness and reliability.
Ethical considerations are addressed through informed consent governance, transparency in synthetic data usage, and AI model auditability. The research adheres to global standards, ensuring compliance with data protection regulations and maintaining high levels of integrity and credibility.
Downstream Processing Market: Key Players Shaping the Future
Leading industry participants such as Thermo Fisher Scientific Inc., GE Healthcare, Sartorius Stedim Biotech S.A., Merck Millipore, Danaher Corporation, 3M Company, Boehringer Ingelheim, Lonza Group AG, Eppendorf AG, Finesse SolutionsInc, among others, are instrumental in driving the evolution of the market. These companies influence market dynamics through continuous innovation, strategic partnerships, and global expansion initiatives. Comprehensive analyses of their financial performance, product portfolios, and SWOT evaluations offer critical insights into their competitive positioning and the overall trajectory of the industry.
Downstream Processing Market: Segments Analysis
Based on the research, Verified Market Reports® has segmented the global Downstream Processing Market into Type, End-Use, Scale, Product Type, Technology, Geography.
To get market data, market insights, and a comprehensive analysis of the Global Downstream Processing Market, please Contact Verified Market Reports®.
By Type
- Filtration
- Chromatography
- Centrifugation
- Purification
By End-Use
- Pharmaceuticals
- Biotechnology
- Food and Beverage
- Cosmetics
By Scale
- Small-scale Processing
- Medium-scale Processing
- Large-scale Processing
By Product Type
- Monoclonal Antibodies
- Recombinant Proteins
- Vaccines
- Cell and Gene Therapies
By Technology
- Single-use Systems
- Traditional Processing Technologies
- Automated Processing Systems
- Advanced Separation Technologies
Downstream Processing Market, By Geography
-
North America
- U.S
- Canada
- Mexico
-
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Netherlands
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Rest of Asia Pacific
-
Latin America
- Brazil
- Argentina
- Chile
- Colombia
-
Middle East & Africa (MEA)
- United Arab Emirates (UAE)
- Saudi Arabia
- South Africa
- Egypt
- Israel
Browse Related Reports:
Global Measurement Technology in Downstream Processing Market Size, Share, Industry Trends & Forecast 2026-2034
Global Downstream Bioprocessing Market Size, Share, Industry Growth & Forecast 2026-2034
Global CBCT/Cone Beam Imaging Market Size, Share, Growth Analysis & Forecast 2026-2034
Global Dental Consumables Market Size, Industry Share & Forecast 2026-2034
Global Microcatheter Market Size, Industry Trends & Forecast 2026-2034
About Us
Verified Market Reports® stands at the forefront as a global leader in Research and Consulting, offering unparalleled analytical research solutions that empower organizations with the insights needed for critical business decisions. Celebrating 10+ years of service, Verified Market Reports has been instrumental in providing founders and companies with precise, up-to-date research data.
With a team of 500+ Analysts and subject matter experts, Verified Market Reports leverages internationally recognized research methodologies for data collection and analyses, covering over 15,000 high impact and niche markets. This robust team ensures data integrity and offers insights that are both informative and actionable, tailored to the strategic needs of businesses across various industries.
Verified Market Reports’ domain expertise is recognized across 14 key industries, including Semiconductor & Electronics, Healthcare & Pharmaceuticals, Energy, Technology, Automobiles, Defense, Mining, Manufacturing, Retail, and Agriculture & Food. In-depth market analysis cover over 52 countries, with advanced data collection methods and sophisticated research techniques being utilized. This approach allows for actionable insights to be furnished by seasoned analysts, equipping clients with the essential knowledge necessary for critical revenue decisions across these varied and vital industries.
Verified Market Reports® is also a member of ESOMAR, an organization renowned for setting the benchmark in ethical and professional standards in market research. This affiliation highlights Verified Market Reports’ dedication to conducting research with integrity and reliability, ensuring that the insights offered are not only valuable but also ethically sourced and respected worldwide.
Contact Us
Mr. Edwyne FernandesVerified Market Reports®US: +1 (650)-781-4080US Toll Free: +1 (800)-782-1768Email: [email protected] Web: https://www.verifiedmarketreports.com/
Logo: https://mma.prnewswire.com/media/2486715/5468917/VM_Reports.jpg
View original content:https://www.prnewswire.co.uk/news-releases/downstream-processing-market-trends-size-surges-to-usd-20-3-billion-by-2033–propelled-by-6-8-cagr—verified-market-reports-302743235.html

Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…